key: cord-1053880-sfwi9fzu
authors: Grant, Michael C.
title: Commentary: Splitting over lumping in mechanical support for ARDS
date: 2020-07-12
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2020.07.010
sha: 6f0cc78ced8b6d44b394e570f432920b522125dd
doc_id: 1053880
cord_uid: sfwi9fzu

nan

The COVID pandemic provides opportunity to evaluate the role of circulatory support in patients with ARDS. Leveraging the moment will require precise definition and meticulous study design.

Central Picture Legend: Michael C. Grant, MD Amidst the present pandemic, clinical researchers are once again confronted with the challenge posed by patients with Acute Respiratory Distress Syndrome (ARDS). As of this writing, more than 2.6 million people in the United States have been diagnosed and 127,000 have succumbed to SARS-CoV-2. 1 Although hospitalization rates are more difficult to track, models forecast admissions to potentially crest 15,000 per day domestically, 2 with a significant percentage of those patients requiring mechanical ventilation due to ARDS. It is often said that adversity breeds innovation and given both the volume and acuity of the moment, opportunity for advancement in our understanding of the management of this vexing disease is undeniable.

In this context, the Letter entitled "Mechanical Ventilation: A Necessary Evil?" introduces a provocative, if not potentially visionary approach to the treatment of ARDS. 3 The letter summarizes the experience at the Medical College of Wisconsin, where multidisciplinary teams are utilizing the transcatheter Protek Duo (LivaNova PLC) Right Ventricular Assist Device to not only support the right ventricle (RV), which is commonly implicated when hemodynamic instability results, but as a means to facilitate extubation, thereby avoiding the known harmful effects of mechanical ventilation in this population. The rationale for the approach has merit and early results among nine consecutive patients are compelling.

The inherent hypothesis of the piece was nonetheless striking in its generality, namely that offloading the RV will mitigate cardiopulmonary compromise. Although this mechanism may contribute to the clinical dilemma, 4 our understanding of the coronavirus disease (COVID-19) is ever-evolving. Some have proposed that the pulmonary impact may be represented by multiple phenotypes, which respond differently to hallmark lung protective ventilation strategies. [5] [6] [7] Furthermore, ARDS is a syndrome with a wide spectrum of presentations and severity. 8 Concomitant neurologic impairment, multiorgan dysfunction and coagulopathy are ranging and unpredictable. When considering the care of these patients, teams should guard against the impulse to cast generalizations and assign interventions in broad swaths. Rather, this disease calls for the development of precise definitions and inclusion criteria to properly classify patients and assign therapies.

It is encouraging to read that the team in Wisconsin is preparing to conduct a multicenter prospective trial, and the devil of such study remains in the details. Recall that Extracorporal Membrane Oxygenation (ECMO) for ARDS -though theoretically ideal as a tool to avoid positive pressure ventilation and ensure lung rest and recovery -remains controversial, in part due to the challenges of conducting appropriate clinical trials. Promising early results suggesting improved mortality in ECMO for ARDS were criticized due to inconsistencies in care among control patients. 9 Unfortunately, a more recent study with improved standardization could not recreate this mortality benefit, potentially the result of high crossover due to the use of ECMO for rescue therapy. 10 Put simply, the management of ARDS is complicated and study of ECMO is messy. While the solution will almost certainly be the result of splitting rather than lumping, centers with adequate resources and expertise are encouraged to leverage this moment to translate innovative anecdotes into new standards of care.

COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed

Centers for Disease Control and Prevention

Mechanical ventilation: A necessary evil?

Incidence and prognostic value of right ventricular failure in acute respiratory distress syndrome

Management of COVID-19 Respiratory Distress

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome